G E Konecny

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer
    G E Konecny
    Division of Gynecologic Surgery, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA
    Br J Cancer 100:89-95. 2009
  2. pmc Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer
    Maike Ihnen
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    Mol Cancer Ther 12:1002-15. 2013
  3. doi request reprint Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells
    Gottfried E Konecny
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    Mol Cancer Ther 12:632-42. 2013
  4. doi request reprint Emerging strategies for the dual inhibition of HER2-positive breast cancer
    Gottfried E Konecny
    David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90404 2429, USA
    Curr Opin Obstet Gynecol 25:55-65. 2013
  5. doi request reprint Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer
    Gottfried E Konecny
    Division of Hematology Oncology, Department of Biomathematics and Biostatistics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
    Clin Cancer Res 17:1591-602. 2011
  6. doi request reprint Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer
    Gottfried E Konecny
    UCLA Translational Oncology Research Lab, David Geffen School of Medicine, University of California Los Angeles, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, 90404 2429, USA
    Breast Cancer Res Treat 120:481-9. 2010
  7. pmc Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
    G E Konecny
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90404 2429, USA
    Br J Cancer 101:1699-708. 2009
  8. ncbi request reprint Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer
    Mark D Pegram
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles 90095 7077, USA
    J Natl Cancer Inst 96:739-49. 2004
  9. pmc Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
    G E Konecny
    Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA
    Br J Cancer 98:1076-84. 2008
  10. ncbi request reprint Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer
    Gottfried E Konecny
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, and Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095 7077, USA
    J Natl Cancer Inst 96:1141-51. 2004

Collaborators

Detail Information

Publications13

  1. pmc HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer
    G E Konecny
    Division of Gynecologic Surgery, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA
    Br J Cancer 100:89-95. 2009
    ..0197; HER2, P=0.7855). We conclude that assessment of HER2 gene amplification and/or EGFR expression may help to select type II EC patients who could benefit from therapeutic strategies targeting both HER2 and EGFR...
  2. pmc Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer
    Maike Ihnen
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    Mol Cancer Ther 12:1002-15. 2013
    ..These results support further clinical evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer...
  3. doi request reprint Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells
    Gottfried E Konecny
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    Mol Cancer Ther 12:632-42. 2013
    ..Dovitinib may have antitumor activity in endometrial cancer beyond FGFR2-mutated cases and may permit greater flexibility in patient selection...
  4. doi request reprint Emerging strategies for the dual inhibition of HER2-positive breast cancer
    Gottfried E Konecny
    David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90404 2429, USA
    Curr Opin Obstet Gynecol 25:55-65. 2013
    ..To review the recently published trials to help us refine and optimize the use of approved HER2-targeted agents (trastuzumab and lapatinib) and highlight future combination strategies for the treatment of HER2-positive breast cancer...
  5. doi request reprint Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer
    Gottfried E Konecny
    Division of Hematology Oncology, Department of Biomathematics and Biostatistics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
    Clin Cancer Res 17:1591-602. 2011
    ..PD-0332991 is a selective inhibitor of the CDK4/6 kinases with the ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range. Here we investigate the role of CDK4/6 inhibition in human ovarian cancer...
  6. doi request reprint Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer
    Gottfried E Konecny
    UCLA Translational Oncology Research Lab, David Geffen School of Medicine, University of California Los Angeles, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, 90404 2429, USA
    Breast Cancer Res Treat 120:481-9. 2010
    ..However, added benefit of IDD chemotherapy itself was not associated with HER2 or TOP2A status...
  7. pmc Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
    G E Konecny
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90404 2429, USA
    Br J Cancer 101:1699-708. 2009
    ....
  8. ncbi request reprint Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer
    Mark D Pegram
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles 90095 7077, USA
    J Natl Cancer Inst 96:739-49. 2004
    ..We characterized interactions between trastuzumab and chemotherapeutic agents commonly used in the treatment of breast cancer...
  9. pmc Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
    G E Konecny
    Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA
    Br J Cancer 98:1076-84. 2008
    ..Expression of EGFR, its ligands, HER3, AR, and post-EMT markers warrant further evaluation to help define patients with HER2-nonoverexpressing endometrial cancer most likely to benefit from lapatinib...
  10. ncbi request reprint Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer
    Gottfried E Konecny
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, and Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095 7077, USA
    J Natl Cancer Inst 96:1141-51. 2004
    ....
  11. ncbi request reprint Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
    Gottfried E Konecny
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, 12 145 Factor Building, 10945 Le Conte Avenue, Los Angeles, CA 90095 1678, USA
    Cancer Res 66:1630-9. 2006
    ..These observations provide a clear biological rationale to test lapatinib as a single agent or in combination with trastuzumab in HER-2-overexpressing breast cancer and in patients with clinical resistance to trastuzumab...
  12. ncbi request reprint Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression
    Gottfried E Konecny
    University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095 1678, USA
    Oncology (Williston Park) 18:32-6. 2004
    ..These findings indicate that trastuzumab plus gemcitabine and trastuzumab plus gemcitabine plus cisplatin or carboplatin are rational combinations to evaluate in clinical trials...
  13. ncbi request reprint Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients
    Gottfried E Konecny
    Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1678, USA
    Clin Cancer Res 10:1706-16. 2004
    ..compare the prognostic significance of VEGF isoforms; and (c). analyze the combined effects of HER-2/neu and VEGF on clinical outcome...